Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Modified Risk Tobacco Product
A bit late but....
In response to your below post….
XXII is not looking to sell a “cure”
The product is a cigarette with 95% less nicotine.
Your last statement is erroneous.
Through studies, etc, a majority of smokers would try VLN cigs.
And yes, there are addicted smokers that want to quit or cut back also.
-----------------------------------------
Thursday, 07/22/21 09:55:41 AM
Post # 53436
Today's news has XXII committed to more expenses
According to XXII they HOPE revenues will follow,
IF XXII ever gets to sell their "cancer" inducer as a "cure!"
No one wants a nonaddictive cigarette other than nonsmokers
Covid 19 and Politics?
Your link is to another of your Forums, the Excel's Coffee Shop.
What you failed to mention what that posters comments are in reference to.
Clicking on the posters RE:post# 24432 link will show that the comments are for a company’s Covid 19 treatment!
Nothing to do with our XXII Forum!
And rather than just posting the comments from post #24433, you need all to see your politics with the inclusion of the “Fiscal Cliff” additive.
Just not proper……………..
One is in "Lock-Up"
iHub Info:
Link: insert-text-here
or copy & paste:
https://investorshub.advfn.com/boards/profilea.aspx?user=6587
"have a nice day"... or a few of them
Where’s “Shorty” today ?
Like you say...
Have a nice day
$2.15…………. 2:41 pm est
Black trumps Red……... Finally !
Well said ………….
Hype vs reality.
Chart
insert-text-here
Scroll down the page to the chart & see the past 1 year.
Plug in for the 7 year chart.
All XXII recently did was bounce off a 5 year low.
MRTP approval still awaits.
You’re spot on with reference to the FDA, specifically.
The “outsiders” influence on the agency’s decisions is great.
From a previous Commissioner of the FDA
In part…. There’s constant pressure from the specific industry, and that specific company’s lobbyists, combined with the politicians who worked on behalf of their patrons.
We all have a vested interest in their upcoming FDA’s decision next month.
XXII has proven its product with lengthy trials.
Here’s hoping we also make it through the FDA’s internal political aspects of approval.
Go XXII
You have some good advice ……
“So I'll say it again as I said before lets try to have a conversation about what is or isn't known about this company and keep the other stuff out of the mix”
All you needed to state was your disagreement with his last statement.
Your derogatory comments of all news services (strangely FOX not included in your list) has a bearing on XXII stock here?
And Quizing ??
This type of political tirade does not belong in this Forum.
I have appreciated your pertinent input on this XXII Forum so far.
As you say, “Let’s keep the other stuff out of the mix”
22nd Century Group to Present its Modified Risk Tobacco Product Application to FDA’s Tobacco Products Scientific Advisory Committee
Meeting is next official step toward possible marketing authorization for 22nd Century Group’s VLN® product in the United States
December 23, 2019 15:39 ET | Source: 22nd Century Group, Inc.
Williamsville, NY, Dec. 23, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced today that the U.S. Food and Drug Administration's (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) will conduct a public hearing on Friday, February 14, 2020, regarding 22nd Century Group’s Modified Risk Tobacco Product (MRTP) application for its VLNC cigarettes under the proposed brand name of VLN® cigarettes.
“We welcome the opportunity to publicly present our MRTP application and detail the science and evidence supporting the reduced exposure claims for VLN® cigarettes,” said Michael Zercher, President and Chief Operating Officer of 22nd Century Group. “This public meeting is an important milestone for 22nd Century Group and for adult smokers who want to reduce their exposure to nicotine.
“We believe that the authorization of our MRTP application would support the FDA’s goal to advance and implement a product standard to reduce the level of nicotine in all cigarettes sold in the U.S. to non-addictive levels. Authorization of our MRTP application for our proprietary VLN® cigarettes also would be further proof of the scientific and technical achievability of the FDA’s proposed product standard to improve public health and save millions of lives.”
On July 17, 2019, the FDA accepted and filed for substantive scientific review the Company’s MRTP application for its unique VLN® cigarettes made from the Company’s proprietary VLNC tobacco. The MRTP application seeks a reduced exposure marketing authorization from the FDA to allow VLN® cigarettes to be marketed with the claim that they contain 95% less nicotine than conventional tobacco cigarettes, as well as other related claims.
22nd Century’s shareholders and the general public are invited to provide comments in support of 22nd Century’s MRTP application on the FDA’s official website at the following link: https://www.regulations.gov/comment?D=FDA-2019-N-0994-0001
During the upcoming TPSAC meeting, representatives from the FDA’s Center for Tobacco Products’ Office of Science and 22nd Century Group will present information about the Company’s MRTP application currently under FDA scientific review. TPSAC members will discuss the available scientific evidence related to the issues and questions posed to TPSAC by FDA about the Company’s MRTP application. TPSAC voting members will vote on specific issues and questions presented by the FDA and on other topics that arise during the committee’s public hearing.
The TPSAC meeting is a required step in the FDA’s review of 22nd Century Group’s request to commercialize VLN® cigarettes in the United States as a “Modified Risk Tobacco Product.” While the advice to the FDA from TPSAC is not binding, FDA nevertheless takes into consideration the insights from TPSAC members, together with public comments and other information made available to the FDA, before making a determination on an MRTP application. TPSAC consists of representatives from public health and non-voting members from the tobacco industry.
The meeting will be open to the general public, and the FDA is accepting written submissions from the public until February 7, 2020. Oral presentations from the public, which will be picked by lottery, are scheduled between 10:45am and 11:45am on February 14, 2020. For those unable to attend in person, the meeting will also be webcast and will be available at the following link: https://collaboration.fda.gov/tpsac021420/.
Since 2011, the Company has supplied more than 28 million SPECTRUM® research cigarettes made with 22nd Century’s VLNC tobacco for use in numerous independent scientific studies funded by the National Institutes of Health (NIH) and other U.S. federal government agencies. Collectively, these studies show that smokers who use 22nd Century’s VLNC cigarettes (i) reduce their nicotine exposure and dependence, (ii) smoke fewer cigarettes per day, (iii) experience reduced withdrawal symptoms, (iv) increase their number of smoke-free days, and (v) double their quit attempts.
Nicotine has long been known as the primary addictive chemical in cigarettes. 22nd Century’s VLN® cigarettes, with at least 95% less nicotine as compared to conventional cigarettes sold in the United States, greatly diminish nicotine exposure versus conventional cigarettes that contain highly addictive levels of nicotine. In a Special Report published in the May 2018 issue of the New England Journal of Medicine, a statistical model funded by the FDA predicted that if all cigarettes in the United States were required to have very low nicotine content, approximately 5 million smokers would quit smoking within a year and that number would increase to a total of 13.0 million within 5 years. By the year 2100, the model estimates that approximately 33 million people would either quit smoking or not start smoking. The model further predicts that 8.5 million deaths will be averted, and 134.4 million life-years will be gained by the year 2100.
"Our regulatory team is very proud of the FDA’s decision on December 17, 2019, to issue marketing orders under our Company’s Premarket Tobacco Product Application (PMTA) permitting our Company’s Moonlight® and Moonlight® menthol cigarettes to be marketed and sold in the United States," said John Pritchard, Vice President of Regulatory Science at 22nd Century Group. "We are excited by the opportunity to present to TPSAC our MRTP application and to taking another step toward driving meaningful change in the tobacco industry.”
What Does TPSAC Do?
Generally, the role of TPSAC is to review and evaluate scientific issues, including safety, dependence, and health issues, relating to tobacco products and provide advice, information, and recommendations to the FDA.
What is TPSAC’s Role in the MRTP Application Review Process?
By law, the FDA must refer MRTP applications to TPSAC, and TPSAC must report its recommendations on the applications. In providing their recommendations, TPSAC members may not necessarily read the entirety of the applications.
The FDA reviews and makes the determination as to whether to authorize an MRTP, and is not required to follow TPSAC recommendations, including votes. However, the FDA takes into consideration TPSAC members’ insights, along with public comments and other information made available to the agency, before making a determination on any MRTP application.
What Happens at TPSAC Meetings on MRTP Applications?
Before a meeting, TPSAC members receive materials prepared by the FDA and the company that provide context to inform TPSAC members’ discussion, including with respect to specific issues and questions from FDA staff that arose during the agency’s scientific review of the MRTP applications. The FDA intends to post all materials provided to TPSAC (redacted in accordance with applicable laws) on the agency’s website two days before a TPSAC meeting.
During a TPSAC meeting, representatives from the company and FDA’s Center for Tobacco Products present information about the company’s MRTP application(s) currently under FDA substantive review. TPSAC members may then discuss available scientific evidence related to issues and questions posed by FDA about the application(s). During this discussion, TPSAC voting members may vote on specific issues and questions or other topics arising during the committee’s discussion.
TPSAC meetings also include time for in-person public comments. Members of the public may attend TPSAC meetings or watch the live webcast.
________________________________________
Hopefully not the usual dump on good news scenario…….
XXII, SEC Form 8-K, 12-3-19
Link >> insert-text-here
Still $0.25 below Tuesday's close…..
XXII’s application for VLN
XXII’s application for VLN is still in the works.
Our Baby just got tossed out with the bath water.
BAT backed out with XXII....
BAT backed out of the agreement with XXII to pursue their own vape and e-cigarette products, rather than searching for the safer cigarette.
insert-text-here
XXII issued this release pertaining to the issue.
insert-text-here
“It appears that BAT is so far behind Philip Morris International in its heat-not-burn product development that BAT has now myopically narrowed its focus to non-combustible devices instead of reduced exposure combustible cigarettes,” stated Henry Sicignano, III,
click on the "insert text here"
to get to the web page article
Article by Baron Karza
Can anyone post a new link, or post the article by Baron Karza on SA about XXII ?
The link in post 49278 by kjgaro is now “dead”. I searched elsewhere but couldn’t find it.
I skimmed over it and went back the next day to finish reading but it was gone.
Thanks
3 Marijuana Stocks to Avoid in May
08 May 2019
Sean Williams, The Motley Fool
https://in.finance.yahoo.com/news/3-marijuana-stocks-avoid-plague-122100163.html
1) Canopy Growth
2) TILT Holdings
3) 22nd Century Group
The final pot stock you'd be wise to avoid in May (which is angled more as a tobacco play than a cannabis play in recent months) is another top-performer in April: 22nd Century Group (NYSEMKT: XXII).
22nd Century Group is a small-cap, $2 stock, so momentum does tend to swing its share price up and down with ease at times. In April, shares received a boost after executives refuted a short-seller attack on the company, and rose following the late-month announcement that the Food and Drug Administration (FDA) had completed a comprehensive inspection of the company's manufacturing facility where Very Low Nicotine Content (VLNC) tobacco cigarettes would be produced. This is one of many steps before hopefully getting the green light from the FDA to produce VLNC cigarettes.
While this all probably seems exciting, I'm not in the last bit sold on the idea that 22nd Century Group's alternative tobacco product is going to be a hit. To begin with, consumers smoke tobacco products for the nicotine buzz. Reducing nicotine content by 97% to eliminate the addiction to nicotine may not sit well with tobacco users, even if the product is given the OK by the FDA.
The other concern here is that Scott Gottlieb has stepped down as the commissioner of the FDA. Gottlieb has been a proponent of tobacco reforms far more than any preceding FDA commissioner, and it's possible that his successors won't fight for lower nicotine content in tobacco cigarettes as he did. 22nd Century Group is pretty much reliant on FDA policy for its VLNC cigarette sales to take off -- and I'm not a big fan of investing based on FDA policy.
Ultimately, there's nothing about 22nd Century's plant-based technology for cannabis and hemp producers, or its VLNC cigarette model, that stands out as buy-worthy. That makes this momentum-based, money-losing stock easily avoidable in May
---------------------------------
The hits keep comin'
Motley Fool - March 10, 2019
The War on Tobacco, E-Cigs, and CBD May Be Coming to an End
Sean Williams, The Motley Fool
https://finance.yahoo.com/news/war-tobacco-e-cigs-cbd-154100039.html
Departures of high-ranking government officials have been somewhat commonplace during the Trump administration, but nothing could have prepared folks for the bombshell announcement that hit the newswires on Tuesday, March 5. It was reported that Scott Gottlieb, commissioner of the U.S. Food and Drug Administration (FDA), would be leaving his post sometime in April to spend more time with his family after putting in nearly two years as the head of the FDA.
Scott Gottlieb was the patient and health advocacy champion this country needed
News of Gottlieb's imminent departure sent immediate ripples through the stock market, with biotech stocks falling. Under Gottlieb's watch, the FDA has approves a record number of experimental pharmaceutical products.
More importantly, though, Gottlieb was arguably viewed as more of a champion of patient rights and health than his predecessors.
He was not afraid to take on the tobacco industry and made curbing teenagers' use of electronic cigarettes one of his top priorities. In fact, in September 2018, a statement from Gottlieb declared e-cigarette use to be an "epidemic" among teens. Said Gottlieb in his released statement, "The FDA won't tolerate a whole generation of young people becoming addicted to nicotine as a trade-off for enabling adults to have unfettered access to these same products." In November, the agency placed new restrictions on e-cig flavors, and less than two months ago, Gottlieb threated to remove e-cigs from the market entirely.
In late July 2017, Gottlieb introduced a bold initiative to reduce the nicotine level in cigarettes to non-addictive levels. Even with adult-use smoking rates in the U.S. hitting an all-time low of 14% in 2017 (about 34 million adults), down dramatically from the 42% of adults who smoked in the mid-1960s, the FDA Commissioner opined that reducing addiction to tobacco cigarettes, and thereby curbing their use, would do more for disease eradication and reduction than all of the medicines they would approve.
More recently, Gottlieb and the FDA cracked down on cannabidiol (CBD) use in food and beverages. CBD is the exceptionally popular nonpsychoactive cannabinoid that can be derived from the cannabis plant or hemp plant and is believed to offer medical benefits. The passage of the Farm Bill, which legalized hemp and hemp-based CBD products, opened the doors for increased CBD sales, but the FDA was quick to put its foot down on the CBD as a food and beverage additive given that little FDA-approved testing has been done on cannabidiol.
Gottlieb's departure opens the door for Big Tobacco and CBD producers to get their way
The tobacco, hemp, and marijuana industries are, or are expected to be, huge, but Gottlieb has been uncompromising on his advocacy of patient health and rights. Unfortunately, his departure might mean the end of many of these fights.
The immediate reaction in 22nd Century Group (NYSEMKT: XXII), which declined as much as 33% in less than an hour after news of Gottlieb's resignation broke, speaks volumes. Known best for its plant biotechnology that extends into the tobacco, hemp, and cannabis industries, 22nd Century Group in December filed its modified-risk tobacco product application with the FDA. Its proprietary product is a Very Low Nicotine Content (VLNC) cigarette which contains 95% less nicotine than traditional tobacco cigarettes. VLNC cigarettes were targeted at Gottlieb's July 2017 initiative to lower nicotine content to sub-addictive levels. But with 22nd Century Group already facing a number of hurdles – i.e., the market for VLNC cigarettes might be minimal, since users smoke tobacco products to get a nicotine high -- Gottlieb's departure may completely end the push for low-content nicotine cigarettes.
Without Gottlieb's presence, e-cigs would may also have new life. As the price of tobacco cigarettes have climbed, vaping product prices have declined, allowing these products to become popular with younger adults that don't have as much disposable income. According to data from the Centers for Disease Control and Prevention, sales of Juul Labs' flash-drive-like vaping device rose by 641% in just one year (2.2 million devices sold in 2016 to 16.2 million devices sold in 2017). Today, approximately 75% e-cig sales nationally are attributed to Juul.
This rapid sales growth and superior market share is a big reason why Marlboro maker Altria (NYSE: MO) announced a $12.8 billion investment in Juul this past December, taking a 35% stake in the company. Altria has increased the price of tobacco products to help offset declining cigarette shipment volumes, but needs new sources of growth to really preserve its long-term outlook. Juul accomplishes this, and Altria will be doing its part by placing Juul vaping pods alongside its Marlboro cigarettes on retail shelves. No Gottlieb potentially means nothing to stand in the way of Altria or Juul from reaching young adults.
We could even witness a change in how CBD or medical cannabis is viewed at the FDA once Scott Gottlieb is gone.
As a refresher, the FDA approved its very first cannabis-derived drug this past June: GW Pharmaceuticals' (NASDAQ: GWPH) Epidiolex. After multiple late-stage studies where Epidiolex regularly led to between a 30% and 40% reduction in seizure frequency from baseline, it made the FDA's decision to approve GW Pharmaceuticals' lead drug easy. But shortly after this CBD-based drug was given the green light, Gottlieb noted that "[W]e do regulate compounds that are making drug claims and we regulate botanical use of marijuana. We have approved compounds derived from marijuana, but there is no demonstrated medical use of botanical marijuana. That's the bottom line." In effect, Gottlieb and the FDA viewed GW Pharmaceuticals' approval as a true one-off, with CBD having no other recognized benefits, whatsoever.
With new leadership at the helm, CBD, or medical marijuana as a whole, could receive another look, or at the very least be granted expedited testing that could expand or modify its use.
As a whole, I believe Gottlieb's advocacy will be sorely missed in Washington. But from an investment standpoint, Big Tobacco, electronic cigarette makers, and the cannabis industry have to be pleased with his departure.
JUUL Advertisement ………….
A FULL page ad has been appearing in the Buffalo News at least every other week.
It’s the ad with the #34 in red dots.
Other JUUL ad’s apparently across the country and overseas.
https://www.google.com/search?q=%22juul%22+full+page+newspaper+ads&tbm=isch&tbo=u&source=univ&sa=X&ved=2ahUKEwj0garg6PLfAhWEy4MKHSuSDa0Q7Al6BAgEEA0&biw=1051&bih=834#imgdii=O-BMQKMK2AUNrM:&imgrc=c9Y5qxiKyRma7M:&spf=1547659458928
Error in stock symbol in previous post ……
Only error in previous post was stock symbol MO should have been PMI.
My point was PMI is still using nicotine to get people addicted to make a buck.
That posting was in response to a now DELETED message.
Entire article >>
https://www.standard.co.uk/news/world/world-leading-cigarette-manufacturer-phillip-morris-international-begins-to-phase-out-cigs-in-favour-a4033981.html
MO “forgot” a couple of key words…..
"World leading cigarette manufacturer Phillip Morris International begins to phase out cigarettes in favour of smoke-free ____ ________ products"
HIGH NICOTINE
Insert in above text
Rejoice….
XXII is up 7.2% YTD
Apropos .............
I close my eyes, only for a moment, and the moment's gone
All my dreams pass before my eyes, a curiosity
Dust in the wind
All they are is dust in the wind
-Kansas- :-0
We're waiting Henry.
The clock is ticking.
Hello ... Anyone out there?
Personal view ……….
I have some agreement jtsmgoblue. I started writing the below last night.
I believe when BAT bailed on XXII, their aim was to transition from traditional cigs and into vaping.
With Altria Group‘s previous and latest moves, I believe they are positioning themselves to be at the forefront with their current acquisitions and deals for both tobacco and cannabis vaping.
In the interim their cig products are still selling without yet a mandate for VLN only smokes.
After VLN rules apply, XXII’s tobacco should have a run.
The FDA might be content with only applying VLN mandates to combustible cigs for now reading Gottlieb’s earlier statement below. We will see.
Gottlieb…. “We are working hard to develop a pathway to put products like e-cigarettes through an appropriate series of regulatory gates to properly evaluate them as an alternative for adults who still want to get access to satisfying levels of nicotine, without all the risks associated with lighting tobacco on fire. And we will continue to encourage the development of potentially less harmful forms of nicotine delivery for currently addicted adult smokers.”
Still waiting, and waiting for some FDA action……
Reply ......
First off, It will not be a nicotine free mandate.
It will be a VLN mandate.
A lower level of nicotine that will be at a non addictive level.
Smokers have had the option to smoke a variety of low or high nicotine cigarettes all these years.
When VLN is federally mandated, the option of smoking addictive high nicotine cigarettes will no longer exist.
At that point if anyone wants to smoke a conventional cigarette, it will be a VLN cigarette.
Another Law Firm gets involved
Was this issue ever addressed by XXII or brought up at the conference call?
My apologies if I just plain missed a company response.
Posted today at eTrade.
Scott+Scott Attorneys at Law LLP Announces Investigation into 22nd Century Group, Inc. (XXII)
10:31 AM ET 11/13/18 | Dow Jones
NEW YORK — Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, is investigating whether 22nd Century Group, Inc. (“22nd Century” or the “Company”) (NYSE: XXII) or certain of its officers and directors violated federal securities laws. If you purchased 22nd Century stock, you are encouraged to contact a Scott+Scott attorney at (844) 818-6980 for more information.
22nd Century is a plant biotechnology company. This investigation concerns whether 22nd Century misled investors.
On October 25, 2018, an article was published on Seeking Alpha stating that a Freedom of Information Act (“FOIA”) request made to the Securities and Exchange Commission (“SEC”) had revealed that 22nd Century was likely under SEC investigation. Yet, an SEC investigation had not been disclosed to investors.
What You Can Do
If you purchased 22nd Century common stock, and you wish to discuss this investigation, please contact attorney Rhiana Swartz at (844) 818-6980, or at rswartz@scott-scott.com.
Esad1, your opinion please…
From the article you listed, is this paragraph:
First things first
Not all companies would agree. Biotech 22nd Century Group (NYSEMKT:XXII) maintains it already grows tobacco with up to 97% less nicotine than tobacco used in conventional cigarettes, and it has produced millions of such cigarettes, albeit solely for drug-abuse research. Those nicotine levels aren't quite low enough to meet the new regulations, but an even bigger question is whether it could scale up production to meet industry demand. In just the second quarter, Altria alone shipped over 27.2 billion cigarettes.
Do you believe the underlined sentence to be just the author’s viewpoint or fact?
I've been under the impression XXII has met the nicotine levels required.
Hanging Tough!
Raid snuffed out!
Go XXII
Hay Gio …………
“If they really wanted to quit they would just stop.”
Really??
Definition of “addiction”
The need or strong desire to do or to have something, or a very strong liking for something
An inability to stop doing or using something, especially something harmful
From eTrade chart ...
I’m seeing a buy of 175k at 11:24.
And sell of 213k at 11:25 and then more selling.
Philip Morris Results Stoke Global Tobacco Stock Sell-Off
April 19,2018 Philip Morris International Inc. led a sell-off in tobacco companies in the U.S. and London after its first-quarter revenue trailed analysts’ estimates.
The stock plunged the most on record, pushing shares of competitors including Imperial Brands Plc, Altria Group Inc. and British American Tobacco Plc deeper into negative territory for 2018.
The latest results from the maker of Marlboro and other top cigarette brands underscored the struggle the industry has had shifting to new products as global smoking rates decline.
More > https://www.bloomberg.com/news/articles/2018-04-19/philip-morris-sales-disappoint-as-cigarette-demand-slips-further
Four Year Anniversary tomorrow ....
Four years ago tomorrow…… All Time High
On 03/10/2014: XXII opened @ 5.90, Closed @ 6.20
Five minutes latter back to $2.86
This is what I believe BiggKatt was referring to.
Could be wrong....
On Jan 23rd The Street Sweeper put out their “Hack” article “Smokin’ 22nd Century (XXII) Will Get Crushed”.
Jan 22 XXII was @ 4.16. Five days later 3.46. Nine trading days later, Feb 5, @ 2.56
http://thestreetsweeper.org/undersurveillance/Smokin__22nd_Century__XXII__Will_Get_Crushed
You Thinking of "The Street Sweeper" ???
7-cigarette-brands-with-lowest-tar-and-nicotine
https://www.insidermonkey.com/blog/7-cigarette-brands-with-lowest-tar-and-nicotine-520699/?singlepage=1
All cigarettes, published 4 years ago
Nicotine level is 2nd number in from the right.
https://www.e-cigarette-forum.com/threads/tar-and-nicotine-content-of-every-cigarette-by-brand-and-variety.498320/
You are of course right……
Sorry, A little “venting” on my part.
I have been a Long throughout with my holdings of XXII.
Also been through a bunch of these “slams” and “pump & dumps”.
I guess it’s just wishful thinking that we’d be done with that crap.
Correction?
Markets dump 10%, XXII down 40%
Does XXII know about that slamming article?
Did anyone send the article from “thestreetsweeper” to XXII Corp?
Didn’t they respond to a similar attack a couple of years ago?
Future plans of PMI & BAT ?
Philip Morris International
https://www.pmi.com/
British American Tobacco
http://www.businessinsider.com/bat-vaping-tobacco-heating-vype-disruption-innovation-tech-2017-4/#theres-been-a-transformation-in-rd-over-the-last-5-years-1